Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .
Four Weeks of IV Iron Supplementation Reduces Perceived Fatigue and Mood Disturbance in Distance Runners
Purpose To determine the effect of intravenous iron supplementation on performance , fatigue and overall mood in runners without clinical iron deficiency . Methods Fourteen distance runners with serum ferritin 30–100 µg·L−1 were r and omly assigned to receive three blinded injections of intravenous ferric-carboxymaltose ( 2 ml , 100 mg , IRON ) or normal saline ( PLACEBO ) over four weeks ( weeks 0 , 2 , 4 ) . Athletes performed a 3,000 m time trial and 10 × 400 m monitored training session on consecutive days at week 0 and again following each injection . Hemoglobin mass ( Hbmass ) was assessed via carbon monoxide rebreathing at weeks 0 and 6 . Fatigue and mood were determined bi-weekly until week 6 via Total Fatigue Score ( TFS ) and Total Mood Disturbance ( TMD ) using the Brief Fatigue Inventory and Brunel Mood Scale . Data were analyzed using magnitude-based inferences , based on the unequal variances t-statistic and Cohen 's Effect sizes ( ES ) . Results Serum ferritin increased in IRON only ( Week 0 : 62.8±21.9 , Week 4 : 128.1±46.6 µg·L−1 ; p = 0.002 ) and remained elevated two weeks after the final injection ( 127.0±66.3 µg·L−1 , p = 0.01 ) , without significant changes in Hbmass . Supplementation had a moderate effect on TMD of IRON ( ES -0.77 ) with scores at week 6 lower than PLACEBO ( ES -1.58 , p = 0.02 ) . Similarly , at week 6 , TFS was significantly improved in IRON vs. PLACEBO ( ES –1.54 , p = 0.05 ) . There were no significant improvements in 3,000 m time in either group ( Week 0 vs. Week 4 ; Iron : 625.6±55.5 s vs. 625.4±52.7 s ; PLACEBO : 624.8±47.2 s vs. 639.1±59.7 s ) ; but IRON reduced their average time for the 10 × 400 m training session at week 2 ( Week 0 : 78.0±6.6 s , Week 2 : 77.2±6.3 ; ES–0.20 , p = 0.004 ) . Conclusion During 6 weeks of training , intravenous iron supplementation improved perceived fatigue and mood of trained athletes with no clinical iron deficiency , without concurrent improvements in oxygen transport capacity or performance
Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .